Background: The neutrophil-to-lymphocyte ratio (NLR) has been investigated in many autoimmune conditions as a biomarker of inflammation and/or disease activity. The role of NLR in AQP4-IgG-positive neuromyelitis optica spectrum disorders (NMOSD) is far from clear. In this study, NLR was evaluated in patients with AQP4-IgG-positive NMOSD at disease onset and its prognostic impact was subsequently assessed. Methods: In this multicenter study, we retrospectively included all recent/newly diagnosed treatment-naïve patients with AQP4-IgG-positive NMOSD (n=90) from three different countries in Latin America (LATAM): Argentina, Ecuador, and Mexico. NLR was compared between AQP4-IgG-positive NMOSD and healthy controls (HC, n = 365). Demographic, clinical, paraclinical (including imaging), and prognostic data at 12 and 24 months were also evaluated. Multivariate regression analysis was used to describe and identify independent associations between the log-transformed NLR and clinical (relapses and EDSS) and imaging (new/enlarging and/or contrast-enhancing MRI lesions) outcomes. Results: NLR was higher in NMOSD patients during the first attack compared with HC (2.9 ± 1.6 vs 1.8 ± 0.6; p<0.0001). Regardless of immunosuppressant's initiation at disease onset, NLR remained higher in NMOSD patients at 12 (2.8 ± 1.3; p<0.0001) and 24 (3.1 ± 1.6; p<0.0001) months. No association was found at 12 and 24 months between the log-transformed NLR and the presence of relapses, new/enlarging and/or contrast-enhancing MRI lesions, and/or physical disability. Conclusions: In this cohort of LATAM patients with AQP4-IgG-positive NMOSD, NLR was abnormally high in attacks but also during follow-up. However, a high NLR was not an independent predictor of clinical or imaging outcomes in our models.
Background: The neutrophil-to-lymphocyte ratio (NLR) has been investigated in many autoimmune conditions as a biomarker of inflammation and/or disease activity. The role of NLR in AQP4-IgG-positive neuromyelitis optica spectrum disorders (NMOSD) is far from clear. In this study, NLR was evaluated in patients with AQP4-IgG-positive NMOSD at disease onset and its prognostic impact was subsequently assessed. Methods: In this multicenter study, we retrospectively included all recent/newly diagnosed treatment-naïve patients with AQP4-IgG-positive NMOSD (n=90) from three different countries in Latin America (LATAM): Argentina, Ecuador, and Mexico. NLR was compared between AQP4-IgG-positive NMOSD and healthy controls (HC, n = 365). Demographic, clinical, paraclinical (including imaging), and prognostic data at 12 and 24 months were also evaluated. Multivariate regression analysis was used to describe and identify independent associations between the log-transformed NLR and clinical (relapses and EDSS) and imaging (new/enlarging and/or contrast-enhancing MRI lesions) outcomes. Results: NLR was higher in NMOSD patients during the first attack compared with HC (2.9 ± 1.6 vs 1.8 ± 0.6; p<0.0001). Regardless of immunosuppressant's initiation at disease onset, NLR remained higher in NMOSD patients at 12 (2.8 ± 1.3; p<0.0001) and 24 (3.1 ± 1.6; p<0.0001) months. No association was found at 12 and 24 months between the log-transformed NLR and the presence of relapses, new/enlarging and/or contrast-enhancing MRI lesions, and/or physical disability. Conclusions: In this cohort of LATAM patients with AQP4-IgG-positive NMOSD, NLR was abnormally high in attacks but also during follow-up. However, a high NLR was not an independent predictor of clinical or imaging outcomes in our models.
Authors: Samira Saadoun; Patrick Waters; Claire MacDonald; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos Journal: Ann Neurol Date: 2012-02-28 Impact factor: 10.422
Authors: Daniel Tesfa; Sofia Ajeganova; Hans Hägglund; Birgitta Sander; Bengt Fadeel; Ingiäld Hafström; Jan Palmblad Journal: Arthritis Rheum Date: 2011-08
Authors: Edgar Carnero Contentti; Vanessa Daccach Marques; Ibis Soto de Castillo; Verónica Tkachuk; Bustos Ariel; Maria C Castillo; Edgardo Cristiano; Gabriel Braga Diégues Serva; Antonio Carlos Dos Santos; Ana Mariel Finkelsteyn; Pablo A López; Liliana Patrucco; Omaira Molina; Juan Pablo Pettinicchi; Vanesa Toneguzzo; Alejandro Caride; Juan Ignacio Rojas Journal: J Neurol Date: 2020-01-13 Impact factor: 4.849
Authors: Edgar Carnero Contentti; Juan Ignacio Rojas; Edgardo Cristiano; Vanessa Daccach Marques; José Flores-Rivera; Marco Lana-Peixoto; Carlos Navas; Regina Papais-Alvarenga; Douglas K Sato; Ibis Soto de Castillo; Jorge Correale Journal: Mult Scler Relat Disord Date: 2020-07-29 Impact factor: 4.339
Authors: Friedemann Paul; Carmen Infante-Duarte; Maria Schroeder-Castagno; Alba Del Rio-Serrato; Andreas Wilhelm; Silvina Romero-Suárez; Patrick Schindler; Cesar Alvarez-González; Ankelien-Solveig Duchow; Judith Bellmann-Strobl; Klemens Ruprecht; Maria Hastermann; Gerald Grütz; Brigitte Wildemann; Sven Jarius; Tanja Schmitz-Hübsch Journal: J Neuroinflammation Date: 2022-10-01 Impact factor: 9.587